Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity

Area of Science:

• Endocrinology
• Biochemistry
• Gerontology

Background:

• Dehydroepiandrosterone (DHEA) is a prevalent adrenal steroid with an unclear biological function.
• Oxidative stress, driven by oxygen-free radicals, is implicated in aging and diseases such as cancer, atherosclerosis, and Alzheimer's disease.

Purpose of the Study:

• To investigate the role of DHEA in inhibiting glucose-6-phosphate dehydrogenase (G6PDH) and its downstream effects on oxidative stress and related diseases.
• To explore the potential therapeutic benefits of DHEA and related steroids in preventing age-related conditions.

Main Methods:

• In vitro and in vivo experimental studies examining DHEA's inhibition of mammalian G6PDH.
• Analysis of NADPH levels and NADPH-dependent oxygen-free radical production.
• Review of epidemiological data on G6PDH deficiency and age-related disease.

Main Results:

• DHEA acts as a potent uncompetitive inhibitor of G6PDH, leading to decreased NADPH levels and reduced oxygen-free radical production.
• Experimental evidence suggests DHEA and related steroids inhibit inflammation, hyperplasia, carcinogenesis, and atherosclerosis by targeting G6PDH and oxidative stress.
• Epidemiological findings in Sardinian males with G6PDH deficiency support a beneficial role of reduced G6PDH activity in longevity and reduced age-related disease.

Conclusions:

• DHEA's inhibition of G6PDH and subsequent reduction in oxidative stress offer a potential mechanism for mitigating age-related diseases.
• Further clinical trials using modified DHEA formulations are warranted to explore its therapeutic potential.
• Targeting G6PDH activity may represent a novel strategy for promoting healthy aging and disease prevention.